Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataElizabeth Dudnik, Nir Peled, Ekaterina Hanovich et al.|Lung Cancer|2017Cited by 104
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)Elizabeth Dudnik, Nir Peled, Elias Bshara et al.|Lung Cancer|2018Cited by 75